Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:2013:252159.
doi: 10.1155/2013/252159. Epub 2013 Dec 17.

Metastatic insulinoma managed with radiolabeled somatostatin analog

Ricardo Costa  1 , Rubens Costa  2 , Carlos E Bacchi  3 , Paulo Almeida Filho  4
Affiliations

Metastatic insulinoma managed with radiolabeled somatostatin analog

Ricardo Costa et al. Case Rep Endocrinol. 2013.

Abstract

Insulinoma is a rare pancreatic neuroendocrine tumor. Overproduction of insulin and associated hypoglycemia are hallmark features of this disease. Diagnosis can be made through demonstration of hypoglycemia and elevated plasma levels of insulin or C-Peptide. Metastatic disease can be detected through computerized tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET)/CT. Somatostatin receptor scintigraphy can be used not only to document metastatic disease but also as a predictive marker of the benefit from therapy with radiolabeled somatostatin analog. Unresectable metastatic insulinomas may present as a major therapeutic challenge for the treating physician. When feasible, resection is the mainstay of treatment. Prevention of hypoglycemia is a crucial goal of therapy for unresectable/metastatic tumors. Diazoxide, hydrochlorothiazide, glucagon, and intravenous glucose infusions have been used for glycemic control yielding temporary and inconsistent results. Sandostatin and its long-acting depot forms have occasionally been used in the treatment of Octreoscan-positive insulinomas. Herein, we report a case of metastatic insulinoma with very difficult glycemic control successfully treated with the radiolabeled somatostatin analog lutetium ((177)LU).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Low-grade neuroendocrine neoplasia of the pancreas. (a) Strong and diffuse expression of chromogranin A. (b) By immunohistochemistry.
Figure 2
Figure 2
Octreoscan: high uptake in focal areas of the liver, left lower quadrant of the abdomen, and cervicothoracic area.
Figure 3
Figure 3
Octreoscan SPECT/CT prior to radiolabeled somatostatin analog lutetium (177LU) administration.
Figure 4
Figure 4
Octreoscan SPECT/CT after 1st infusion of radiolabeled somatostatin analog lutetium (177LU) administration.
Figure 5
Figure 5
See this image and copyright information in PMC

References

    1. Service FJ, McMahon MM, O’Brien PC, Ballard DJ. Functioning insulinoma: incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clinic Proceedings. 1991;66(7):711–719. - PubMed
    1. Wild D, Bomanji JB, Benkert P, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. Journal of Nuclear Medicine. 2013;54(3):364–372. - PubMed
    1. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. Journal of Clinical Oncology. 2005;23(12):2754–2762. - PubMed
    1. Fischbach J, Gut P, Matysiak-Grzes M, et al. Combined octreotide and peptide receptor radionuclide therapy ((90)Y-DOTA-TATE) in case of malignant insulinoma. Neuro Endocrinology Letters. 2012;33(3):273–278. - PubMed
    1. Reutova EV, Orel NF, Besova NS, Artemova EV, Smirnova NB, Gorbunova VA. A case of effective treatment of malignant insulin-producing pancreatic tumor. Terapevticheskii Arkhiv. 1999;71(10):44–45. - PubMed

LinkOut - more resources